AGS-16C3F, an ADC targeting ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3, CD203a) conjugated to MMAF, is now a subject of phase II clinical trials for the therapy of renal cell carcinoma (RCC) [8,70]. The gene discussed is ENPP3; the disease is renal cell carcinoma.